• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Oct31
Nanobiotix SA Enters into Royalty Monetization Agreement with Healthcare Royalty
07:01
Oct24
Nanobiotix transfers head and neck cancer trial control to Johnson & Johnson
06:00
Oct4
Nanobiotix SA ADR Reports Significant H1 2025 Revenue Growth, Narrowed Net Loss
03:56
Oct1
Nanobiotix SA released FY2025 Semi-Annual Earnings on September 30 (EST), actual revenue USD 30.01 M (forecast USD 8.154 M), actual EPS USD -0.1278 (forecast USD -0.4448)
03:00
Nanobiotix SA released FY2025 Q2 earnings on September 30 (EST), actual revenue USD 15.59 M, actual EPS USD -0.0664
03:00
Nanobiotix SA released FY2025 Q1 earnings on September 30 (EST), actual revenue USD 14.42 M, actual EPS USD -0.0614
03:00

Schedules & Filings

Schedules
Filings
Sep30
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 15.59 M, Net Income -3.151 M, EPS -0.0664

Apr2
Earning Release(EST)

FY2024 Q4 Earning Release (USD) Revenue -8.57 M, Net Income -24.06 M, EPS -0.5088

Sep18
Earning Release(EST)

FY2024 Q2 Earning Release (USD) Revenue 4.975 M, Net Income -11.72 M, EPS -0.2485

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
ASPC
24.010
+78.91%
+10.590
PCLA
0.4050
+74.49%
+0.173
DTCK
0.3951
+66.08%
+0.157
SOPA
1.820
+58.26%
+0.670
ECDA
1.150
+46.50%
+0.365
GAUZ
1.470
+44.12%
+0.450
CELG.RT
0.0698
+39.60%
+0.020
ASPCR
0.2500
+38.89%
+0.070
PAVS
2.170
+37.34%
+0.590
CUE
0.3248
+34.77%
+0.084
View More